Subscribe
shutterstock_1854288799_pcruciatti
pcruciatti / Shutterstock.com
30 August 2022AmericasStaff Writer

Moderna hits Pfizer and BioNTech with COVID-19 vaccine patent suit

Moderna has taken Pfizer and its German partner BioNTech to court, alleging that the pair copied Moderna’s technology when developing their COVID-19 vaccine.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
Pfizer and partner hit back in COVID-19 vaccine dispute
8 December 2022   Big pharma firm accused of copying technology when developing vaccine | Dispute will also play out in Germany | BioNTech | Moderna.
Big Pharma
Big pharma firm hits back in COVID-19 tech dispute
6 September 2022   CureVac accuses Pfizer and its German partner of infringing patented tech in landmark COVID-19 treatment | The pharma giant says that the patents are invalid
Big Pharma
Arbutus, Genevant sue Moderna over COVID-19 vaccine tech
1 March 2022   Arbutus Biopharma and Genevant Sciences are jointly suing Moderna over royalties from the sales of its COVID-19 vaccine, which allegedly uses their tech for a drug-delivery system without authorisation.


Editor's picks

LSPN: In-house ‘chess game’ is the same, but the rules have changed
Americas
LSPN: In-house ‘chess game’ is the same, but the rules have changed
9 May 2025

Editor's picks

Americas
LSPN: In-house ‘chess game’ is the same, but the rules have changed
9 May 2025
Americas
LSPN: Counsel grapple with AI’s impact on training and critical thinking
8 May 2025
Americas
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
6 May 2025
Americas
Why US patent reform is ‘essential’ for US economic prosperity and security
29 April 2025
Europe
Meril v Edwards: Harmonisation of obviousness at the UPC and the EPO
24 April 2025
Americas
WIPR Diversity & Inclusion reveals Top 100 People in IP for 2025
24 April 2025

More on this story

Big Pharma
Pfizer and partner hit back in COVID-19 vaccine dispute
8 December 2022   Big pharma firm accused of copying technology when developing vaccine | Dispute will also play out in Germany | BioNTech | Moderna.
Big Pharma
Big pharma firm hits back in COVID-19 tech dispute
6 September 2022   CureVac accuses Pfizer and its German partner of infringing patented tech in landmark COVID-19 treatment | The pharma giant says that the patents are invalid
Big Pharma
Arbutus, Genevant sue Moderna over COVID-19 vaccine tech
1 March 2022   Arbutus Biopharma and Genevant Sciences are jointly suing Moderna over royalties from the sales of its COVID-19 vaccine, which allegedly uses their tech for a drug-delivery system without authorisation.

More on this story

Big Pharma
Pfizer and partner hit back in COVID-19 vaccine dispute
8 December 2022   Big pharma firm accused of copying technology when developing vaccine | Dispute will also play out in Germany | BioNTech | Moderna.
Big Pharma
Big pharma firm hits back in COVID-19 tech dispute
6 September 2022   CureVac accuses Pfizer and its German partner of infringing patented tech in landmark COVID-19 treatment | The pharma giant says that the patents are invalid
Big Pharma
Arbutus, Genevant sue Moderna over COVID-19 vaccine tech
1 March 2022   Arbutus Biopharma and Genevant Sciences are jointly suing Moderna over royalties from the sales of its COVID-19 vaccine, which allegedly uses their tech for a drug-delivery system without authorisation.

More features

LSPN: In-house ‘chess game’ is the same, but the rules have changed
Life sciences leaders recognised at LSPN Awards USA 2025
UK-India trade deal is ‘a missed opportunity for UK pharma’, says industry body
LSPN: Counsel grapple with AI’s impact on training and critical thinking
'Nothing can stand in the way of our work': Ukraine resumes IP system
LSPN: Trump's policy storm causing chaos and confusion
Taylor Wessing expands in Europe with Paris team
LSPN: Using ‘the patentee’s friend’ in Section 112 claims